Based on physiologic properties, which patients are eligible for short- vs long-acting GLP-1 RAs? And why is the combination of basal insulin and GLP-1 RA a reasonable strategy?

Based on physiologic properties, which patients are eligible for short- vs long-acting GLP-1 RAs? And why is the combination of basal insulin and GLP-1 RA a reasonable strategy?

Based on physiologic properties, which patients are eligible for short- vs long-acting GLP-1 RAs? And why is the combination of basal insulin and GLP-1 RA a reasonable strategy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Filip Knop, MD

Filip Knop, MD

Diabetes Research Division
Department of Internal Medicine
Gentofte University Hospital
Copenhagen, Denmark